No Data
Noil Immune --- For the fiscal year ending December 2024, the in-house drug development business and the joint pipeline will continue to be promoted.
Noil Immune Biotech <4893> announced its financial results for the fiscal year ending December 2024 on the 14th. Business revenue was 0.007 billion yen (compared to 0.316 billion yen in the previous term), operating loss was 1.069 billion yen (compared to a loss of 0.775 billion yen in the previous term), recurring loss was 0.962 billion yen (compared to a loss of 1.127 billion yen in the previous term), and net loss for the year was 0.964 billion yen (compared to a loss of 1.13 billion yen in the previous term). As for the company's business status for the fiscal year, the self-developed drug discovery business based on PRIME technology and the joint pipeline will continue.
Noile-Immune Biotech: Summary of financial results for the fiscal year ending 2024/12 [Japanese GAAP] (unconsolidated)
Kirin HD, Matsukiyo Cocok, Dentsu Group, Rakuten Group (14th) (1379-5368)
The above Calendar is merely a schedule and is subject to change due to the company's circumstances.--------------------------------------- February 14 (Friday) <1379> Hokuto <1380> Akigawa Boku-en <1417> Mirait-Wan <142A> Jinjibu <1438> Gifu Landscaping <1443> Giken HD <1447> SAAF HD <145A> Elizbee<
Noile Immune ETC [Stocks with appeal viewed from Volume changes]
Stock closing prices compared to the previous day, Volume * <2814> Sato Foods 21102155600 * <4893> Noile Immune 195215296000 * <5724> Asaka Riken 85826206900 * <7859> Almedio 339576372700 * <6864> NF HD 1529229920900 * <1443> Giken HD 1905262600 * <6366> Chiyo Construction 337376659200 * <5074> Tes Holdings 289354
Individual stock information.
EF Code <9211.T> continues to rise significantly. It will become a consolidated subsidiary of Ciel Zero, an IT engineering service company based in Osaka. In the future, Ciel Zero will utilize its engineering expertise, experience, IT personnel, and development resources to further expand its business. GATECH <3491.T> drops significantly, declining for three consecutive days. In the overseas market, mainly in Europe and Asia (excluding the USA and Canada), there will be a public offering of 4,072,400 new shares.
Emerging Markets Stock Digest: GA TECH has fallen significantly for three consecutive days, and HENNGE has hit the upper limit.
＜4592＞ SanBio 767 +25 significantly rebounding. The financial estimates for the January 2025 period have been revised upward from a previous forecast of a 3.359 billion yen deficit to a 2.736 billion yen deficit (compared to the prior period's performance of a 2.644 billion yen deficit). The year-end Exchange Rates have been confirmed, and the amount related to foreign currency loans and related claims against consolidated subsidiaries is expected to result in an exchange gain of approximately 0.623 billion yen, leading to a reduction in the deficit. The operating profit and loss forecast indicates a 3.339 billion yen deficit (compared to the same period's 4.539 billion yen deficit.